
Eileen M O’Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study An interview with: Eileen M O’Reilly MD, Medical Oncologist, Professor of Medicine, Winthrop Rockefeller Chair in Me

























